Taliglucerase alfa: safety and efficacy across 6 clinical studies in adults and children with Gaucher disease. (Q50281421)

28 February 2018

4 references

24 March 2019

22 April 2019

25 April 2019

28 September 2019

Taliglucerase alfa: safety and efficacy across 6 clinical studies in adults and children with Gaucher disease. (English)

1 reference

28 February 2018

4 references

24 March 2019

22 April 2019

25 April 2019

28 September 2019

1 reference

28 September 2019

Ari Zimran

1

1 reference

28 February 2018

Michael Wajnrajch

series ordinal

2

1 reference

28 February 2018

Betina Hernandez

series ordinal

3

1 reference

28 February 2018

Gregory M Pastores

series ordinal

4

1 reference

28 February 2018

language of work or name

1 reference

23 February 2018

5 references

28 February 2018

Orphanet Journal of Rare Diseases

24 March 2019

22 April 2019

25 April 2019

28 September 2019

5 references

28 February 2018

24 March 2019

22 April 2019

25 April 2019

28 September 2019

13

1 reference

28 February 2018

page(s)

36

1 reference

28 February 2018

issue

1

1 reference

28 February 2018

Creative Commons Attribution 4.0 International

copyright license

4 references

24 March 2019

22 April 2019

25 April 2019

on focus list of Wikimedia project

28 September 2019

copyright status

copyrighted

0 references

ScienceSource

0 references

exact match

https://scigraph.springernature.com/pub.10.1186/s13023-018-0776-8

0 references

cites work

Long-term efficacy and safety results of taliglucerase alfa through 5years in adult treatment-naïve patients with Gaucher disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5824466

Long-term efficacy and safety results of taliglucerase alfa up to 36 months in adult treatment-naïve patients with Gaucher disease

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5824466

Enzyme replacement therapy with taliglucerase alfa: 36-month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5824466

Pharmacokinetics of Novel Plant Cell-Expressed Taliglucerase Alfa in Adult and Pediatric Patients with Gaucher Disease

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5824466

Safety and efficacy of two dose levels of taliglucerase alfa in pediatric patients with Gaucher disease

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5824466

Management of Gaucher disease: enzyme replacement therapy

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5824466

Taliglucerase alfa: an enzyme replacement therapy using plant cell expression technology

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5824466

Glycosylation and functionality of recombinant β-glucocerebrosidase from various production systems

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5824466

Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5824466

Osteopenia in Gaucher disease develops early in life: response to imiglucerase enzyme therapy in children, adolescents and adults

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5824466

Velaglucerase alfa, a human recombinant glucocerebrosidase enzyme replacement therapy for type 1 Gaucher disease.

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5824466

Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5824466

Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5824466

The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5824466

Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5824466

Pediatric non-neuronopathic Gaucher disease: presentation, diagnosis and assessment. Consensus statements

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5824466

The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5824466

Adult-type Gaucher disease in children: genetics, clinical features and enzyme replacement therapy.

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5824466

Gaucher disease. Clinical, laboratory, radiologic, and genetic features of 53 patients

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5824466

Long-term safety and efficacy of taliglucerase alfa in pediatric Gaucher disease patients who were treatment-naïve or previously treated with imiglucerase

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5824466

Improving the accuracy of MRI spleen and liver volume measurements: a phase III Gaucher disease clinical trial setting as a model

14 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5824466

Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease

14 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/29471850

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/29471850

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with i

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/29471850

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/S13023-018-0776-8

1 reference

28 February 2018

Dimensions Publication ID

0 references

1 reference

28 February 2018

PubMed ID

29471850

1 reference

28 February 2018